Selected Financial Data
since 2005
Income Statement
Vertex Pharmaceuticals Inc., selected items from income statement, long-term trends
US$ in thousands
| 12 months ended: | Revenues | Income (loss) from operations | Net income (loss) |
|---|---|---|---|
| Dec 31, 2025 | 12,001,300) | 4,173,300) | 3,953,200) |
| Dec 31, 2024 | 11,020,100) | (232,900) | (535,600) |
| Dec 31, 2023 | 9,869,200) | 3,832,000) | 3,619,600) |
| Dec 31, 2022 | 8,930,700) | 4,307,400) | 3,322,000) |
| Dec 31, 2021 | 7,574,400) | 2,782,100) | 2,342,100) |
| Dec 31, 2020 | 6,205,683) | 2,856,290) | 2,711,647) |
| Dec 31, 2019 | 4,162,821) | 1,197,566) | 1,176,810) |
| Dec 31, 2018 | 3,047,597) | 635,150) | 2,096,896) |
| Dec 31, 2017 | 2,488,652) | 123,243) | 263,484) |
| Dec 31, 2016 | 1,702,177) | 9,936) | (112,052) |
| Dec 31, 2015 | 1,032,336) | (466,879) | (556,334) |
| Dec 31, 2014 | 580,415) | (692,412) | (738,555) |
| Dec 31, 2013 | 1,211,975) | (903,448) | (445,028) |
| Dec 31, 2012 | 1,527,042) | 2,332) | (107,032) |
| Dec 31, 2011 | 1,410,626) | 113,820) | 29,574) |
| Dec 31, 2010 | 143,370) | (696,077) | (754,626) |
| Dec 31, 2009 | 101,889) | (614,012) | (642,178) |
| Dec 31, 2008 | 175,504) | (462,708) | (459,851) |
| Dec 31, 2007 | 199,012) | (419,792) | (391,279) |
| Dec 31, 2006 | 216,356) | (229,038) | (206,891) |
| Dec 31, 2005 | 160,890) | (149,872) | (203,417) |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
The income statement reveals a period of significant volatility followed by substantial growth. Initial years demonstrate consistent losses, transitioning to profitability and then experiencing further fluctuations before achieving sustained positive results. Revenues exhibit a dramatic increase beginning in 2011, while operational and net income demonstrate a similar, though delayed, positive trend.
- Revenue Trend
- From 2005 to 2007, revenues experienced initial growth followed by a decline. Revenues remained relatively stable, albeit low, from 2008 through 2010. A substantial increase in revenue is observed in 2011, continuing through 2025, with consistent year-over-year growth. The most significant revenue increases occurred between 2019 and 2025. Revenue reached 12.001 billion in 2025.
- Operational Income Trend
- Operational income consistently reported losses from 2005 to 2009, with losses increasing in magnitude each year. A slight profit was recorded in 2011, followed by a significant loss in 2013. Operational income became positive again in 2015 and demonstrated consistent growth through 2022. A substantial loss was recorded in 2023, followed by a return to profitability in 2024 and a significant increase in 2025.
- Net Income Trend
- Net income mirrored the trend of operational income, with consistent losses from 2005 to 2009. Net income turned positive in 2011, but experienced a loss in 2013. Similar to operational income, net income became positive in 2015 and grew consistently until 2022. A substantial net loss was recorded in 2023, followed by a significant recovery in 2025. The largest net income occurred in 2025, at 3.953 billion.
The period between 2005 and 2010 represents a phase of substantial financial challenges. The years 2011-2019 mark a period of recovery and growth, culminating in significant profitability by 2019. The year 2023 represents an anomaly with a substantial net loss, but the company rebounded strongly in 2025, indicating resilience and potential for continued positive performance.
- Relationship between Revenues and Profitability
- A strong correlation exists between revenue growth and improvements in both operational and net income. The substantial revenue increases beginning in 2011 appear to be a primary driver of the subsequent profitability. However, the 2023 results demonstrate that revenue growth does not automatically guarantee profitability, suggesting potential cost factors or other influences impacting the bottom line.
AI Ask an analyst for more
Balance Sheet: Assets
Vertex Pharmaceuticals Inc., selected items from assets, long-term trends
US$ in thousands
| Current assets | Total assets | |
|---|---|---|
| Dec 31, 2025 | 11,201,000) | 25,643,000) |
| Dec 31, 2024 | 9,596,400) | 22,533,200) |
| Dec 31, 2023 | 14,144,200) | 22,730,200) |
| Dec 31, 2022 | 13,234,800) | 18,150,900) |
| Dec 31, 2021 | 9,560,600) | 13,432,500) |
| Dec 31, 2020 | 8,133,379) | 11,751,808) |
| Dec 31, 2019 | 4,822,829) | 8,318,465) |
| Dec 31, 2018 | 3,843,109) | 6,245,898) |
| Dec 31, 2017 | 2,648,963) | 3,546,014) |
| Dec 31, 2016 | 1,831,540) | 2,896,787) |
| Dec 31, 2015 | 1,407,153) | 2,498,875) |
| Dec 31, 2014 | 1,546,511) | 2,334,679) |
| Dec 31, 2013 | 1,588,576) | 2,319,041) |
| Dec 31, 2012 | 1,589,585) | 2,759,288) |
| Dec 31, 2011 | 1,331,254) | 2,204,280) |
| Dec 31, 2010 | 1,057,039) | 1,725,446) |
| Dec 31, 2009 | 1,307,026) | 1,955,488) |
| Dec 31, 2008 | 867,581) | 980,479) |
| Dec 31, 2007 | 496,851) | 601,477) |
| Dec 31, 2006 | 771,406) | 921,579) |
| Dec 31, 2005 | 385,055) | 548,998) |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
The company’s current assets and total assets exhibited significant fluctuations and overall growth throughout the period examined. Initial values in 2005 were relatively modest, but both metrics experienced substantial increases in subsequent years, particularly from 2016 onwards.
- Current Assets Trend
- Current assets demonstrated considerable volatility. After an initial increase from 2005 to 2006, a decrease was observed in 2007. Subsequent growth occurred through 2009, followed by a decline in 2010. From 2011 to 2015, current assets remained relatively stable, fluctuating within a narrow range. A marked acceleration in growth began in 2016, continuing through 2019. The most substantial increase occurred between 2019 and 2020, reaching a peak in 2022. A significant decrease in current assets was then observed in 2023, followed by modest increases in 2024 and 2025.
- Total Assets Trend
- Total assets mirrored the general trend of current assets, though with less pronounced volatility. A substantial increase occurred between 2005 and 2009, driven largely by an increase in current assets. A decrease was observed in 2006 and 2007. From 2010 to 2015, total assets remained relatively stable. Similar to current assets, a period of rapid growth commenced in 2016, accelerating through 2019. The period from 2019 to 2022 saw the most dramatic increase in total assets. A decrease was observed in 2023, followed by increases in 2024 and 2025, though not to the levels seen in 2022.
- Relationship Between Current and Total Assets
- Throughout the period, current assets consistently represented a substantial portion of total assets. The proportion fluctuated, but generally remained above 60%. The significant increases in current assets from 2016 onwards were a primary driver of the overall growth in total assets. The decrease in current assets in 2023 also contributed to a decrease in total assets during that year.
The observed trends suggest a dynamic asset structure, with significant growth concentrated in the later years of the period. The fluctuations in both current and total assets warrant further investigation to understand the underlying drivers, such as changes in cash, accounts receivable, inventory, and long-term investments.
AI Ask an analyst for more
Balance Sheet: Liabilities and Stockholders’ Equity
Vertex Pharmaceuticals Inc., selected items from liabilities and stockholders’ equity, long-term trends
US$ in thousands
| Current liabilities | Total liabilities | Total long-term obligations | Shareholders’ equity | |
|---|---|---|---|---|
| Dec 31, 2025 | 3,861,200) | 6,977,200) | 112,200) | 18,665,800) |
| Dec 31, 2024 | 3,564,600) | 6,123,600) | 118,000) | 16,409,600) |
| Dec 31, 2023 | 3,547,400) | 5,149,800) | 426,700) | 17,580,400) |
| Dec 31, 2022 | 2,742,100) | 4,238,200) | 471,600) | 13,912,700) |
| Dec 31, 2021 | 2,142,000) | 3,332,500) | 556,700) | 10,100,000) |
| Dec 31, 2020 | 1,877,533) | 3,064,993) | 581,476) | 8,686,815) |
| Dec 31, 2019 | 1,334,827) | 2,233,221) | 568,869) | 6,085,244) |
| Dec 31, 2018 | 1,120,292) | 1,810,695) | 586,821) | 4,435,203) |
| Dec 31, 2017 | 807,260) | 1,503,708) | 583,902) | 2,028,579) |
| Dec 31, 2016 | 792,537) | 1,558,596) | 821,335) | 1,156,582) |
| Dec 31, 2015 | 506,349) | 1,405,247) | 810,981) | 939,967) |
| Dec 31, 2014 | 368,254) | 1,238,496) | 807,141) | 1,075,006) |
| Dec 31, 2013 | 397,829) | 962,636) | 489,691) | 1,356,405) |
| Dec 31, 2012 | 432,624) | 1,524,906) | 683,201) | 999,180) |
| Dec 31, 2011 | 392,348) | 1,238,768) | 455,950) | 786,843) |
| Dec 31, 2010 | 474,783) | 1,221,473) | 536,991) | 503,973) |
| Dec 31, 2009 | 284,883) | 859,142) | 153,836) | 1,096,346) |
| Dec 31, 2008 | 216,564) | 741,605) | 287,500) | 238,874) |
| Dec 31, 2007 | 199,279) | 330,182) | 19,997) | 271,295) |
| Dec 31, 2006 | 251,014) | 415,644) | 121,747) | 505,935) |
| Dec 31, 2005 | 100,243) | 309,822) | 180,097) | 239,176) |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
The liabilities and stockholders’ equity of the company demonstrate significant fluctuations and overall growth over the period from 2005 to 2025. Current liabilities exhibit a generally increasing trend, with notable surges in specific years. Total liabilities show a more volatile pattern, punctuated by substantial increases, while stockholders’ equity experiences periods of rapid expansion followed by relative stabilization. Long-term obligations fluctuate considerably, indicating shifts in the company’s financing strategies.
- Current Liabilities
- Current liabilities began at US$100.243 million in 2005 and increased substantially to US$251.014 million in 2006. After a decrease in 2007, they generally trended upward, with a significant increase from US$792.537 million in 2016 to US$1,877.533 million in 2020. This growth continued, reaching US$3,547.400 million in 2022 before a slight decrease to US$3,861.200 million in 2023 and a further increase to US$3,564.600 million in 2024. The most recent value in 2025 is US$3,861,200 million. This suggests an increasing reliance on short-term financing or a rapid expansion of operational needs.
- Total Liabilities
- Total liabilities experienced a considerable increase from US$309.822 million in 2005 to US$415.644 million in 2006. A significant jump occurred between 2008 and 2009, rising from US$741.605 million to US$859.142 million. Following a dip in 2013, total liabilities increased substantially, reaching US$3,064.993 million in 2020 and peaking at US$5,149.800 million in 2022. The value decreased to US$6,123.600 million in 2023 and US$6,977,200 million in 2025. This pattern indicates periods of aggressive debt financing followed by potential deleveraging or restructuring.
- Total Long-Term Obligations
- Long-term obligations began at US$180.097 million in 2005 and decreased to US$121.747 million in 2006. A substantial decline occurred through 2007, reaching US$19.997 million. The obligations increased again in 2008, but remained relatively stable between US$455.950 million and US$821.335 million from 2011 to 2014. A decrease is observed from 2017 to 2022, followed by a further decline to US$118.000 million in 2023 and US$112.200 million in 2025. This suggests a shift away from long-term debt financing in recent years.
- Shareholders’ Equity
- Shareholders’ equity demonstrated substantial growth from US$239.176 million in 2005 to US$505.935 million in 2006. A significant increase occurred in 2009, reaching US$1,096.346 million. Following a decrease in 2010, equity continued to grow, peaking at US$6,085.244 million in 2019. It then increased to US$10,100.000 million in 2021 and US$13,912.700 million in 2022, before decreasing to US$16,409.600 million in 2023 and US$18,665,800 million in 2025. This indicates strong profitability and/or successful equity financing activities, particularly in the latter half of the analyzed period.
Overall, the company’s balance sheet reflects a dynamic financial position. The increasing trend in current liabilities, coupled with fluctuations in total liabilities and long-term obligations, suggests a complex financing strategy. The substantial growth in shareholders’ equity indicates a strengthening financial foundation, although recent decreases warrant further investigation.
AI Ask an analyst for more
Cash Flow Statement
Vertex Pharmaceuticals Inc., selected items from cash flow statement, long-term trends
US$ in thousands
| 12 months ended: | Net cash provided by (used in) operating activities | Net cash (used in) provided by investing activities | Net cash provided by (used in) financing activities |
|---|---|---|---|
| Dec 31, 2025 | 3,631,400) | (945,400) | (2,261,300) |
| Dec 31, 2024 | (492,600) | (3,770,000) | (1,494,900) |
| Dec 31, 2023 | 3,537,300) | (3,141,700) | (562,200) |
| Dec 31, 2022 | 4,129,900) | (321,100) | (67,700) |
| Dec 31, 2021 | 2,643,500) | (340,900) | (1,478,000) |
| Dec 31, 2020 | 3,253,505) | 99,388) | (505,281) |
| Dec 31, 2019 | 1,569,330) | (1,235,318) | 126,773) |
| Dec 31, 2018 | 1,270,286) | (202,158) | (71,219) |
| Dec 31, 2017 | 844,942) | (437,681) | 68,404) |
| Dec 31, 2016 | 236,103) | 104,469) | 133,271) |
| Dec 31, 2015 | (365,432) | 268,856) | 188,919) |
| Dec 31, 2014 | (513,199) | 73,959) | 497,376) |
| Dec 31, 2013 | (51,570) | (54,130) | 180,884) |
| Dec 31, 2012 | 267,841) | (425,817) | 172,204) |
| Dec 31, 2011 | 143,735) | 212,412) | (124,238) |
| Dec 31, 2010 | (635,442) | 7,301) | 425,057) |
| Dec 31, 2009 | (427,586) | (508,732) | 999,006) |
| Dec 31, 2008 | (226,482) | (360,650) | 620,738) |
| Dec 31, 2007 | (252,476) | 405,166) | (10,190) |
| Dec 31, 2006 | (22,475) | (208,471) | 365,865) |
| Dec 31, 2005 | (172,054) | (1,732) | 197,456) |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
The cash flow statement reveals significant fluctuations across all three activities – operating, investing, and financing – over the period examined. A notable shift in operating cash flow occurred around 2011, transitioning from substantial negative values to positive figures, with a marked increase in recent years. Investing activities demonstrate a pattern of alternating between cash usage and cash provision, while financing activities exhibit considerable variability, influenced by periods of both significant inflows and outflows.
- Operating Activities
- From 2005 through 2010, net cash provided by operating activities was consistently negative, peaking at a loss of approximately 635.4 million US dollars in 2010. A dramatic turnaround began in 2011, with a positive cash flow of 143.7 million US dollars. This positive trend continued, with substantial increases in subsequent years, reaching a high of 4.13 billion US dollars in 2022. A significant decrease was observed in 2023, resulting in a net cash outflow of 492.6 million US dollars, followed by a recovery to 3.63 billion US dollars in 2025. This suggests a growing operational maturity followed by a recent, potentially temporary, setback.
- Investing Activities
- Net cash used in investing activities was prominent in the earlier years of the period, particularly in 2006 with an outflow of 208.5 million US dollars. A substantial inflow occurred in 2007 (405.2 million US dollars), followed by a return to outflows. The period from 2015 to 2019 saw considerable investment, evidenced by significant cash outflows, culminating in a large outflow of 1.24 billion US dollars in 2019. More recently, large cash outflows were observed in 2022 and 2023, reaching 3.14 and 3.77 billion US dollars respectively, indicating substantial capital expenditure or acquisitions. The pattern suggests a cyclical approach to investment, with periods of expansion followed by consolidation.
- Financing Activities
- Financing activities displayed considerable volatility. Significant inflows were recorded in 2005 (197.5 million US dollars) and 2006 (365.9 million US dollars), followed by a net outflow in 2007. Large inflows were again observed in 2009 (999.0 million US dollars) and 2010 (425.1 million US dollars). The period from 2018 to 2021 saw a shift towards net cash outflows, with a particularly large outflow of 1.48 billion US dollars in 2021. Outflows continued in 2023 and 2024, reaching 562.2 and 2.26 billion US dollars respectively, potentially indicating debt repayment or shareholder returns. The fluctuations suggest active management of capital structure and funding sources.
Overall, the cash flow statement indicates a company that has evolved from a cash-consuming entity to a significant cash generator through its operating activities. However, this positive trend is coupled with substantial and fluctuating investment and financing activities, suggesting a dynamic business strategy involving ongoing capital allocation and financial management.
AI Ask an analyst for more
Per Share Data
Vertex Pharmaceuticals Inc., selected data per share, long-term trends
US$
| 12 months ended: | Basic earnings per share 1 | Diluted earnings per share 2 | Dividend per share 3 |
|---|---|---|---|
| Dec 31, 2025 | 15.46 | 15.32 | 0.00 |
| Dec 31, 2024 | -2.08 | -2.08 | 0.00 |
| Dec 31, 2023 | 14.05 | 13.89 | 0.00 |
| Dec 31, 2022 | 12.97 | 12.82 | 0.00 |
| Dec 31, 2021 | 9.09 | 9.01 | 0.00 |
| Dec 31, 2020 | 10.44 | 10.29 | 0.00 |
| Dec 31, 2019 | 4.58 | 4.51 | 0.00 |
| Dec 31, 2018 | 8.24 | 8.09 | 0.00 |
| Dec 31, 2017 | 1.06 | 1.04 | 0.00 |
| Dec 31, 2016 | -0.46 | -0.46 | 0.00 |
| Dec 31, 2015 | -2.31 | -2.31 | 0.00 |
| Dec 31, 2014 | -3.14 | -3.14 | 0.00 |
| Dec 31, 2013 | -1.98 | -1.98 | 0.00 |
| Dec 31, 2012 | -0.50 | -0.50 | 0.00 |
| Dec 31, 2011 | 0.14 | 0.14 | 0.00 |
| Dec 31, 2010 | -3.77 | -3.77 | 0.00 |
| Dec 31, 2009 | -3.71 | -3.71 | 0.00 |
| Dec 31, 2008 | -3.27 | -3.27 | 0.00 |
| Dec 31, 2007 | -3.03 | -3.03 | 0.00 |
| Dec 31, 2006 | -1.83 | -1.83 | 0.00 |
| Dec 31, 2005 | -2.28 | -2.28 | 0.00 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1, 2, 3 Data adjusted for splits and stock dividends.
The per share earnings of the company demonstrate a significant evolution over the observed period. From 2005 through 2009, both basic and diluted earnings per share (EPS) were consistently negative, indicating net losses during those years. The magnitude of the losses fluctuated, peaking in 2007 and 2009.
A turning point occurred in 2011, with both basic and diluted EPS becoming positive, albeit marginally. Subsequent years showed volatility, with a return to negative EPS in 2012 before resuming a positive trajectory. From 2014 onwards, a clear upward trend in EPS is evident, accelerating significantly from 2017. The highest EPS values were recorded in 2020, 2022, and 2023, with 2023 showing the highest value at $14.05 for basic EPS and $13.89 for diluted EPS.
However, 2024 witnessed a substantial decline, with both basic and diluted EPS turning negative again, reaching -$2.08. This represents a significant reversal of the prior positive trend. Preliminary figures for 2025 suggest a recovery, with both basic and diluted EPS returning to positive territory, reaching $15.46 and $15.32 respectively.
- Basic Earnings Per Share
- The trend in basic EPS reveals a prolonged period of losses followed by substantial growth and a recent, sharp decline and subsequent recovery. The volatility observed, particularly in 2024, warrants further investigation.
- Diluted Earnings Per Share
- The diluted EPS trend closely mirrors that of basic EPS, indicating that the impact of potentially dilutive securities has been relatively consistent over time. The differences between basic and diluted EPS remain small throughout the period.
- Dividend Per Share
- No dividend payments were recorded throughout the observed period. This suggests the company prioritized reinvesting earnings or faced financial constraints that precluded dividend distributions.
The substantial fluctuations in EPS, particularly the negative value in 2024 followed by a strong rebound in 2025, suggest the company’s profitability is sensitive to specific events or market conditions. The absence of dividends throughout the period indicates a focus on internal funding of growth initiatives or a period of financial consolidation.
AI Ask an analyst for more